BACKGROUND Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. OBJECTIVES In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated according to concurrent lipoprotein(a) levels. METHODS ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent acute coronary syndromes receiving optimized statin treatment. In 4,351 patients (23.0%), screening or randomization LDL-C was <70 mg/dL (median 69.4 mg/dL; interquartile range: 64.3–74.0 mg/dL); in 14,573 patients (77.0%), both determinations were ≥70 mg/dL (median 94.0 mg/dL; interquartile range: 83.2–111.0 mg/dL). RESULTS In the lower LDL-C subgroup, MACE rates were 4.2 and 3.1 per 100 patient-years among placebo-treated patients with baseline lipoprotein(a) greater than or less than or equal to the median (13.7 mg/dL). Corresponding adjusted treatment hazard ratios were 0.68 (95% confidence interval [Cl]: 0.52–0.90) and 1.11 (95% Cl: 0.83–1.49), with treatment-lipoprotein(a) interaction on MACE ( P interaction = 0.017). In the higher LDL-C subgroup, MACE rates were 4.7 and 3.8 per 100 patient-years among placebo-treated patients with lipoprotein(a) >13.7 mg/dL or ≤13.7 mg/dL; corresponding adjusted treatment hazard ratios were 0.82 (95% Cl: 0.72–0.92) and 0.89 (95% Cl: 0.75–1.06), with P interaction = 0.43. CONCLUSIONS In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402 )
BACKGROUND.Despite the achievements in the management of coronary heart disease (CHD), there is a need to appropriately tailor the long-term management strategies and risk stratification, particularly after percutaneous coronary intervention (PCI) because of non-ST-elevation acute coronary syndrome (NSTE-ACS) or chronic coronary syndrome (CCS). OBJECTIVES The Present study aimed to (i) evaluate the long-term cardiovascular prognostic value of oxidative stress markers, arterial stiffness parameters, and hemogram-derived inflammatory indices, and (ii) compare the long-term predictive performance of the above-mentioned markers with the periprocedural SYNTAX score II (SS-II) in Georgian patients following PCI. METHODS After PCI because of NSTE-ACS or CCS, the annual incidence of 6-component MACEs, and values of the oxidative profile, arterial stiffness measurements, and hemogram-derived indices (HDI) were measured during the 36-month follow-up period in the development (100 patients with NSTE-ACS) and validation cohorts (91 patients with CCS), respectively. RESULTS By the multiple regression analysis NLR (0.505±0.069, p<0.0001), OXpr (0.181±0.076, p=0.018), SBPao (0.174±0.076, p=0.023), and PLR (0.164±0.056, p=0.004) are positively correlated with 36-month MACEs. CONCLUSIONS The oxidative stress profile, central systolic blood pressure, and hemogram-derived indices such as neutrophil-lymphocyte and monocytelymphocyte ratios may be used as novel independent predictors of long-term major adverse cardiovascular events. KEYWORDS Central systolic blood pressure (SBPao); chronic coronary syndrome (CCS); major adverse cardiovascular events (MACEs); neutrophil-tolymphocyte ratio (NLR); non-ST-elevation acute coronary syndrome (NSTE-ACS); oxidative profile (OXpr); platelet-to-lymphocyte ratio (PLR). BACKGROUNDespite the latest achievements in the management of coronary heart disease (CHD), there is a residual risk of subsequent major cardiovascular events (MACEs). 1 The risk of future dramatic events is highly heterogeneous, and patients may differ in the degree of benefit received from existing treatment. 2-4 Therefore, there is a need to appropriately tailor the long-term management strategies and risk stratification in patients after percutaneous coronary intervention (PCI) because of non-ST-elevation acute coronary syndrome (NSTE-ACS) or chronic coronary syndrome (CCS).A recent index, the SYNTAX score II (SS-II) is the most potent tool to predict a long-term major cardiovascular event in patients undergoing coronary revascularization. 5-8 However, this predictive index never has been validated in a Georgian acute coronary syndrome (ACS) patient.The accumulated evidence of the recent decades provides deeper insights into the pathophysiology of cardiovascular diseases and accentuates the prognostic significance of new markers related to arterial stiffness, oxidative stress, and lowgrade systemic inflammation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.